HK Stock Market Move | TENNOR THERAP-B (06872) rises nearly 3%; recently entered into a supplementary agreement to the exclusive commercialization cooperation agreement with Grand Life Sciences

date
13:45 18/11/2026
avatar
GMT Eight
TENNOR THERAP-B (06872) rose nearly 3%, up 2.43% as of press time to HK$69.5, with a turnover of HK$3.5779 million.
TENNOR THERAP-B (06872) rose nearly 3%, up 2.43% as of press time to HK$69.5, with turnover of HK$3.5779 million. On the news front, TENNOR THERAP-B announced that the company has been actively advancing the China marketing authorization review process for the first indication of rifasutenizol and the corresponding commercialization preparations. To align with the relevant review process, ensure that the cooperation arrangements are consistent with the expected commercialization timeline of rifasutenizol, and further consolidate the long-term cooperative relationship between the company and Grand Life Sciences, the board of directors is pleased to announce that on November 12, 2026, the company entered into a supplementary agreement to the cooperation agreement with Grand Life Sciences. Accordingly, both parties agreed to extend the relevant period under the cooperation agreement during which Grand Life Sciences has the right to unilaterally terminate the cooperation agreement by written notice due to the company's failure to obtain the China marketing authorization for the first indication of rifasutenizol by the specified date, from December 31, 2026 to July 31, 2027.